April 15, 2024 06:44 AM EDTUpdated 06:58 AM
R&D

Roche’s Columvi pass­es Phase 3 lym­phoma test as com­pe­ti­tion with Ab­b­Vie, Gen­mab con­tin­ues

Ayisha Sharma

News Reporter

Roche’s Columvi is on the path to a full ap­proval and po­ten­tial­ly a la­bel ex­pan­sion in an ear­li­er lym­phoma set­ting af­ter hit­ting the pri­ma­ry end­point …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times